Partially  ||| S:0 E:10 ||| RB
hydrolysed  ||| S:10 E:21 ||| CD
100 ||| S:21 E:24 ||| CD
%  ||| S:24 E:26 ||| NN
whey-based  ||| S:26 E:37 ||| JJ
infant  ||| S:37 E:44 ||| NN
formula  ||| S:44 E:52 ||| NN
and  ||| S:52 E:56 ||| CC
the  ||| S:56 E:60 ||| DT
prevention  ||| S:60 E:71 ||| NN
of  ||| S:71 E:74 ||| IN
atopic  ||| S:74 E:81 ||| JJ
dermatitis ||| S:81 E:91 ||| NN
:  ||| S:91 E:93 ||| :
comparative  ||| S:93 E:105 ||| FW
pharmacoeconomic  ||| S:105 E:122 ||| FW
analyses  ||| S:122 E:131 ||| FW
Clinical  ||| S:131 E:140 ||| FW
trials  ||| S:140 E:147 ||| NNS
have  ||| S:147 E:152 ||| VBP
demonstrated  ||| S:152 E:165 ||| VBN
that  ||| S:165 E:170 ||| IN
the  ||| S:170 E:174 ||| DT
risk  ||| S:174 E:179 ||| NN
of  ||| S:179 E:182 ||| IN
developing  ||| S:182 E:193 ||| VBG
atopic  ||| S:193 E:200 ||| JJ
dermatitis  ||| S:200 E:211 ||| NN
is  ||| S:211 E:214 ||| VBZ
reduced  ||| S:214 E:222 ||| VBN
when  ||| S:222 E:227 ||| WRB
using  ||| S:227 E:233 ||| VBG
hydrolysed  ||| S:233 E:244 ||| JJ
formulas  ||| S:244 E:253 ||| NNS
to  ||| S:253 E:256 ||| TO
feed  ||| S:256 E:261 ||| VB
infants  ||| S:261 E:269 ||| NNS
with  ||| S:269 E:274 ||| IN
a  ||| S:274 E:276 ||| DT
documented  ||| S:276 E:287 ||| JJ
risk  ||| S:287 E:292 ||| NN
of  ||| S:292 E:295 ||| IN
atopy  ||| S:295 E:301 ||| NNS
( ||| S:301 E:302 ||| -LRB-
i.e.  ||| S:302 E:307 ||| FW
an  ||| S:307 E:310 ||| DT
affected  ||| S:310 E:319 ||| JJ
parent  ||| S:319 E:326 ||| NN
and ||| S:326 E:329 ||| CC
/ ||| S:329 E:330 ||| NNP
or  ||| S:330 E:333 ||| CC
sibling ||| S:333 E:340 ||| CD
) ||| S:340 E:341 ||| -RRB-
when  ||| S:341 E:346 ||| WRB
breastfeeding  ||| S:346 E:360 ||| NN
is  ||| S:360 E:363 ||| VBZ
not  ||| S:363 E:367 ||| RB
practised ||| S:367 E:376 ||| VBN
.  ||| S:376 E:378 ||| .
However ||| S:378 E:385 ||| RB
,  ||| S:385 E:387 ||| ,
little  ||| S:387 E:394 ||| RB
is  ||| S:394 E:397 ||| VBZ
known  ||| S:397 E:403 ||| VBN
about  ||| S:403 E:409 ||| IN
the  ||| S:409 E:413 ||| DT
cost-effectiveness  ||| S:413 E:432 ||| JJ
of  ||| S:432 E:435 ||| IN
using  ||| S:435 E:441 ||| VBG
hydrolysed  ||| S:441 E:452 ||| JJ
formulas ||| S:452 E:460 ||| NNS
.  ||| S:460 E:462 ||| .
Consequently ||| S:462 E:474 ||| RB
,  ||| S:474 E:476 ||| ,
economic  ||| S:476 E:485 ||| JJ
analyses  ||| S:485 E:494 ||| NNS
in  ||| S:494 E:497 ||| IN
5  ||| S:497 E:499 ||| CD
European  ||| S:499 E:508 ||| JJ
countries  ||| S:508 E:518 ||| NNS
( ||| S:518 E:519 ||| -LRB-
Denmark ||| S:519 E:526 ||| NNP
,  ||| S:526 E:528 ||| ,
France ||| S:528 E:534 ||| NNP
,  ||| S:534 E:536 ||| ,
Germany ||| S:536 E:543 ||| NNP
,  ||| S:543 E:545 ||| ,
Spain  ||| S:545 E:551 ||| NNP
and  ||| S:551 E:555 ||| CC
Switzerland ||| S:555 E:566 ||| NNP
)  ||| S:566 E:568 ||| -RRB-
have  ||| S:568 E:573 ||| VBP
evaluated  ||| S:573 E:583 ||| VBN
the  ||| S:583 E:587 ||| DT
costs  ||| S:587 E:593 ||| NNS
and  ||| S:593 E:597 ||| CC
cost-effectiveness  ||| S:597 E:616 ||| JJ
of  ||| S:616 E:619 ||| IN
a  ||| S:619 E:621 ||| DT
specific  ||| S:621 E:630 ||| JJ
brand  ||| S:630 E:636 ||| NN
of  ||| S:636 E:639 ||| IN
100 ||| S:639 E:642 ||| CD
%  ||| S:642 E:644 ||| NN
whey-based  ||| S:644 E:655 ||| NN
partially  ||| S:655 E:665 ||| RB
hydrolysed  ||| S:665 E:676 ||| JJ
infant  ||| S:676 E:683 ||| NN
formula ||| S:683 E:690 ||| NN
,  ||| S:690 E:692 ||| ,
NAN-HAÂ®  ||| S:692 E:700 ||| NNP
( ||| S:700 E:701 ||| -LRB-
PHF-W ||| S:701 E:706 ||| NNP
)  ||| S:706 E:708 ||| -RRB-
compared  ||| S:708 E:717 ||| VBN
with  ||| S:717 E:722 ||| IN
a  ||| S:722 E:724 ||| DT
cow ||| S:724 E:727 ||| NN
's  ||| S:727 E:730 ||| POS
milk  ||| S:730 E:735 ||| NN
standard  ||| S:735 E:744 ||| JJ
formula  ||| S:744 E:752 ||| NN
( ||| S:752 E:753 ||| -LRB-
SF ||| S:753 E:755 ||| NNP
)  ||| S:755 E:757 ||| -RRB-
in  ||| S:757 E:760 ||| IN
the  ||| S:760 E:764 ||| DT
prevention  ||| S:764 E:775 ||| NN
of  ||| S:775 E:778 ||| IN
atopic  ||| S:778 E:785 ||| JJ
dermatitis  ||| S:785 E:796 ||| NN
in  ||| S:796 E:799 ||| IN
at-risk  ||| S:799 E:807 ||| JJ
children ||| S:807 E:815 ||| NNS
.  ||| S:815 E:817 ||| .
This  ||| S:817 E:822 ||| DT
review  ||| S:822 E:829 ||| NN
synthesises  ||| S:829 E:841 ||| VBD
the  ||| S:841 E:845 ||| DT
findings  ||| S:845 E:854 ||| NNS
of  ||| S:854 E:857 ||| IN
these  ||| S:857 E:863 ||| DT
studies ||| S:863 E:870 ||| NNS
.  ||| S:870 E:872 ||| .
Cost-effectiveness  ||| S:872 E:891 ||| JJ
analyses  ||| S:891 E:900 ||| NNS
( ||| S:900 E:901 ||| -LRB-
CEA ||| S:901 E:904 ||| NNP
)  ||| S:904 E:906 ||| -RRB-
used  ||| S:906 E:911 ||| VBD
a  ||| S:911 E:913 ||| DT
decision-analytic  ||| S:913 E:931 ||| JJ
model  ||| S:931 E:937 ||| NN
to  ||| S:937 E:940 ||| TO
determine  ||| S:940 E:950 ||| VB
treatment  ||| S:950 E:960 ||| NN
pathways ||| S:960 E:968 ||| NN
,  ||| S:968 E:970 ||| ,
resource  ||| S:970 E:979 ||| JJ
utilisation  ||| S:979 E:991 ||| NN
and  ||| S:991 E:995 ||| CC
costs  ||| S:995 E:1001 ||| NNS
associated  ||| S:1001 E:1012 ||| VBN
with  ||| S:1012 E:1017 ||| IN
the  ||| S:1017 E:1021 ||| DT
management  ||| S:1021 E:1032 ||| NN
of  ||| S:1032 E:1035 ||| IN
atopic  ||| S:1035 E:1042 ||| JJ
dermatitis  ||| S:1042 E:1053 ||| NN
in  ||| S:1053 E:1056 ||| IN
healthy  ||| S:1056 E:1064 ||| JJ
at-risk  ||| S:1064 E:1072 ||| JJ
newborns  ||| S:1072 E:1081 ||| NNS
who  ||| S:1081 E:1085 ||| WP
were  ||| S:1085 E:1090 ||| VBD
not  ||| S:1090 E:1094 ||| RB
exclusively  ||| S:1094 E:1106 ||| RB
breastfed ||| S:1106 E:1115 ||| VBN
.  ||| S:1115 E:1117 ||| .
The  ||| S:1117 E:1121 ||| DT
model  ||| S:1121 E:1127 ||| NN
had  ||| S:1127 E:1131 ||| VBD
a  ||| S:1131 E:1133 ||| DT
12-month  ||| S:1133 E:1142 ||| JJ
horizon  ||| S:1142 E:1150 ||| NN
and  ||| S:1150 E:1154 ||| CC
applied  ||| S:1154 E:1162 ||| VBD
reimbursement  ||| S:1162 E:1176 ||| JJ
rates  ||| S:1176 E:1182 ||| NNS
of  ||| S:1182 E:1185 ||| IN
60-100 ||| S:1185 E:1191 ||| CD
%  ||| S:1191 E:1193 ||| NN
depending  ||| S:1193 E:1203 ||| VBG
on  ||| S:1203 E:1206 ||| IN
the  ||| S:1206 E:1210 ||| DT
country ||| S:1210 E:1217 ||| NN
.  ||| S:1217 E:1219 ||| .
Outcomes  ||| S:1219 E:1228 ||| NNP
were  ||| S:1228 E:1233 ||| VBD
considered  ||| S:1233 E:1244 ||| VBN
from  ||| S:1244 E:1249 ||| IN
the  ||| S:1249 E:1253 ||| DT
perspective  ||| S:1253 E:1265 ||| NN
of  ||| S:1265 E:1268 ||| IN
the  ||| S:1268 E:1272 ||| DT
public  ||| S:1272 E:1279 ||| JJ
healthcare  ||| S:1279 E:1290 ||| JJ
system  ||| S:1290 E:1297 ||| NN
( ||| S:1297 E:1298 ||| -LRB-
e.g.  ||| S:1298 E:1303 ||| CD
the  ||| S:1303 E:1307 ||| DT
Ministry  ||| S:1307 E:1316 ||| NNP
of  ||| S:1316 E:1319 ||| IN
Health ||| S:1319 E:1325 ||| NNP
;  ||| S:1325 E:1327 ||| :
MOH ||| S:1327 E:1330 ||| NNP
) ||| S:1330 E:1331 ||| -RRB-
,  ||| S:1331 E:1333 ||| ,
family  ||| S:1333 E:1340 ||| NN
and  ||| S:1340 E:1344 ||| CC
society ||| S:1344 E:1351 ||| NN
.  ||| S:1351 E:1353 ||| .
The  ||| S:1353 E:1357 ||| DT
final  ||| S:1357 E:1363 ||| JJ
outcome  ||| S:1363 E:1371 ||| NN
was  ||| S:1371 E:1375 ||| VBD
the  ||| S:1375 E:1379 ||| DT
incremental  ||| S:1379 E:1391 ||| JJ
cost-effectiveness  ||| S:1391 E:1410 ||| JJ
ratio  ||| S:1410 E:1416 ||| NN
per  ||| S:1416 E:1420 ||| IN
avoided  ||| S:1420 E:1428 ||| JJ
case  ||| S:1428 E:1433 ||| NN
of  ||| S:1433 E:1436 ||| IN
atopic  ||| S:1436 E:1443 ||| JJ
dermatitis  ||| S:1443 E:1454 ||| NNS
( ||| S:1454 E:1455 ||| -LRB-
ICER ||| S:1455 E:1459 ||| NNP
)  ||| S:1459 E:1461 ||| -RRB-
for  ||| S:1461 E:1465 ||| IN
PHF-W  ||| S:1465 E:1471 ||| JJ
versus  ||| S:1471 E:1478 ||| CC
SF ||| S:1478 E:1480 ||| NNP
.  ||| S:1480 E:1482 ||| .
A  ||| S:1482 E:1484 ||| DT
cost-minimisation  ||| S:1484 E:1502 ||| JJ
analysis  ||| S:1502 E:1511 ||| NN
was  ||| S:1511 E:1515 ||| VBD
also  ||| S:1515 E:1520 ||| RB
performed  ||| S:1520 E:1530 ||| VBN
to  ||| S:1530 E:1533 ||| TO
compare  ||| S:1533 E:1541 ||| VB
PHF-W  ||| S:1541 E:1547 ||| JJ
with  ||| S:1547 E:1552 ||| IN
extensively  ||| S:1552 E:1564 ||| FW
hydrolysed  ||| S:1564 E:1575 ||| FW
formulas  ||| S:1575 E:1584 ||| FW
( ||| S:1584 E:1585 ||| -LRB-
EHF ||| S:1585 E:1588 ||| NNP
) ||| S:1588 E:1589 ||| -RRB-
.  ||| S:1589 E:1591 ||| .
The  ||| S:1591 E:1595 ||| DT
base-case  ||| S:1595 E:1605 ||| JJ
CEA  ||| S:1605 E:1609 ||| NNP
produced  ||| S:1609 E:1618 ||| VBD
ICERs  ||| S:1618 E:1624 ||| JJ
per  ||| S:1624 E:1628 ||| IN
avoided  ||| S:1628 E:1636 ||| JJ
case  ||| S:1636 E:1641 ||| NN
for  ||| S:1641 E:1645 ||| IN
PHF-W  ||| S:1645 E:1651 ||| JJ
versus  ||| S:1651 E:1658 ||| CC
SF  ||| S:1658 E:1661 ||| NNP
of  ||| S:1661 E:1664 ||| IN
EUR  ||| S:1664 E:1668 ||| NNP
982-1,343  ||| S:1668 E:1678 ||| NNP
( ||| S:1678 E:1679 ||| -LRB-
MOH  ||| S:1679 E:1683 ||| NNP
perspective ||| S:1683 E:1694 ||| NN
) ||| S:1694 E:1695 ||| -RRB-
,  ||| S:1695 E:1697 ||| ,
EUR  ||| S:1697 E:1701 ||| NNP
-2,202  ||| S:1701 E:1708 ||| NNP
to  ||| S:1708 E:1711 ||| TO
-624  ||| S:1711 E:1716 ||| CD
( ||| S:1716 E:1717 ||| -LRB-
family  ||| S:1717 E:1724 ||| NN
perspective ||| S:1724 E:1735 ||| NN
)  ||| S:1735 E:1737 ||| -RRB-
indicating  ||| S:1737 E:1748 ||| VBG
savings ||| S:1748 E:1755 ||| NNS
,  ||| S:1755 E:1757 ||| ,
and  ||| S:1757 E:1761 ||| CC
EUR  ||| S:1761 E:1765 ||| NNP
-1,220  ||| S:1765 E:1772 ||| NNP
to  ||| S:1772 E:1775 ||| TO
719  ||| S:1775 E:1779 ||| CD
from  ||| S:1779 E:1784 ||| IN
the  ||| S:1784 E:1788 ||| DT
societal  ||| S:1788 E:1797 ||| JJ
perspective ||| S:1797 E:1808 ||| NN
.  ||| S:1808 E:1810 ||| .
The  ||| S:1810 E:1814 ||| DT
main  ||| S:1814 E:1819 ||| JJ
costs  ||| S:1819 E:1825 ||| NNS
related  ||| S:1825 E:1833 ||| VBN
to  ||| S:1833 E:1836 ||| TO
formula  ||| S:1836 E:1844 ||| NN
( ||| S:1844 E:1845 ||| -LRB-
MOH  ||| S:1845 E:1849 ||| NNP
and  ||| S:1849 E:1853 ||| CC
society ||| S:1853 E:1860 ||| NN
)  ||| S:1860 E:1862 ||| -RRB-
and  ||| S:1862 E:1866 ||| CC
time  ||| S:1866 E:1871 ||| NN
loss  ||| S:1871 E:1876 ||| NN
( ||| S:1876 E:1877 ||| -LRB-
family ||| S:1877 E:1883 ||| NN
) ||| S:1883 E:1884 ||| -RRB-
.  ||| S:1884 E:1886 ||| .
In  ||| S:1886 E:1889 ||| IN
the  ||| S:1889 E:1893 ||| DT
cost-minimisation  ||| S:1893 E:1911 ||| JJ
analysis ||| S:1911 E:1919 ||| NN
,  ||| S:1919 E:1921 ||| ,
PHF-W  ||| S:1921 E:1927 ||| JJ
yielded  ||| S:1927 E:1935 ||| JJ
savings  ||| S:1935 E:1943 ||| NNS
of  ||| S:1943 E:1946 ||| IN
between  ||| S:1946 E:1954 ||| IN
EUR  ||| S:1954 E:1958 ||| NNP
4.3  ||| S:1958 E:1962 ||| CD
and  ||| S:1962 E:1966 ||| CC
120  ||| S:1966 E:1970 ||| CD
million  ||| S:1970 E:1978 ||| CD
compared  ||| S:1978 E:1987 ||| VBN
with  ||| S:1987 E:1992 ||| IN
EHF-whey  ||| S:1992 E:2001 ||| JJ
when  ||| S:2001 E:2006 ||| WRB
the  ||| S:2006 E:2010 ||| DT
latter  ||| S:2010 E:2017 ||| NN
was  ||| S:2017 E:2021 ||| VBD
used  ||| S:2021 E:2026 ||| VBN
in  ||| S:2026 E:2029 ||| IN
prevention ||| S:2029 E:2039 ||| NN
.  ||| S:2039 E:2041 ||| .
In  ||| S:2041 E:2044 ||| IN
conclusion ||| S:2044 E:2054 ||| NN
,  ||| S:2054 E:2056 ||| ,
PHF-W  ||| S:2056 E:2062 ||| NNP
was  ||| S:2062 E:2066 ||| VBD
cost-effective  ||| S:2066 E:2081 ||| JJ
versus  ||| S:2081 E:2088 ||| CC
SF  ||| S:2088 E:2091 ||| NNP
in  ||| S:2091 E:2094 ||| IN
the  ||| S:2094 E:2098 ||| DT
prevention  ||| S:2098 E:2109 ||| NN
of  ||| S:2109 E:2112 ||| IN
atopic  ||| S:2112 E:2119 ||| JJ
dermatitis  ||| S:2119 E:2130 ||| NN
and  ||| S:2130 E:2134 ||| CC
cost  ||| S:2134 E:2139 ||| NN
saving  ||| S:2139 E:2146 ||| VBG
compared  ||| S:2146 E:2155 ||| VBN
with  ||| S:2155 E:2160 ||| IN
EHF  ||| S:2160 E:2164 ||| NNP
when  ||| S:2164 E:2169 ||| WRB
used  ||| S:2169 E:2174 ||| VBN
in  ||| S:2174 E:2177 ||| IN
prevention ||| S:2177 E:2187 ||| NN
.  ||| S:2187 E:2189 ||| .
